Ventyx Biosciences, Inc. (VTYX): Price and Financial Metrics
GET POWR RATINGS... FREE!
VTYX Stock Price Chart Interactive Chart >
VTYX Price/Volume Stats
| Current price | $42.46 | 52-week high | $44.98 |
| Prev. close | $43.95 | 52-week low | $9.50 |
| Day low | $41.84 | Volume | 733,700 |
| Day high | $43.95 | Avg. volume | 676,728 |
| 50-day MA | $33.37 | Dividend yield | N/A |
| 200-day MA | $24.66 | Market Cap | 2.40B |
Ventyx Biosciences, Inc. (VTYX) Company Bio
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis, inflammatory bowel disease, psoriatic arthritis, and lupus. It also develops VTX002, an oral sphingosine 1 phosphate receptor 1 modulator that has completed phase I clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor for the treatment of systemic inflammatory diseases, such as cardiovascular, hepatic, renal, and rheumatologic diseases. In addition, the company develops CNS-penetrant NLRP3 inhibitors. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in Encinitas, California.
Latest VTYX News From Around the Web
Below are the latest news stories about VENTYX BIOSCIENCES INC that investors may wish to consider to help them evaluate VTYX as an investment opportunity.
Are You Looking for a Top Momentum Pick? Why Ventyx Biosciences, Inc. (VTYX) is a Great ChoiceDoes Ventyx Biosciences, Inc. (VTYX) have what it takes to be a top stock pick for momentum investors? Let's find out. |
Wall Street Analysts Think Ventyx Biosciences, Inc. (VTYX) Could Surge 38.99%: Read This Before Placing a BetThe consensus price target hints at a 39% upside potential for Ventyx Biosciences, Inc. (VTYX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
Ventyx Biosciences Announces Pipeline Updates and Highlights Strategic Priorities at Investor R&D DayPhase 2 clinical trials of VTX958 (TYK2 inhibitor) in plaque psoriasis, Crohn’s disease and psoriatic arthritis are ongoing with topline Phase 2 data in plaque psoriasis expected in Q4 2023 The Phase 2 trial of VTX002 (S1P1R modulator) in ulcerative colitis is on track to complete enrollment by mid-2023; new pharmacodynamic data support best-in-class potential Releases new data highlighting attractive profiles of NLRP3 inhibitors VTX2735 and VTX3232 Discloses new small molecule discovery program |
Here's Why Momentum in Ventyx Biosciences, Inc. (VTYX) Should Keep goingVentyx Biosciences, Inc. (VTYX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen. |
Ventyx Biosciences Appoints Allison J. Hulme, Ph.D. and Onaiza Cadoret-Manier to its Board of DirectorsNew directors replace current directors Richard Gaster, M.D., Ph.D., Aaron Royston, M.D., and Jigar ChokseyENCINITAS, Calif., Jan. 12, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced the appointment of Allison J. Hulme, Ph.D. and Onaiza Cadoret-Manier to its board of directors. Dr |
VTYX Price Returns
| 1-mo | 32.60% |
| 3-mo | 61.75% |
| 6-mo | 132.53% |
| 1-year | 255.91% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 29.49% |
| 2022 | 65.11% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...